RenovoRx, Inc.

NASDAQ:RNXT

Biotechnology

Healthcare
$1.12 -0.86%

-$0.01 today

Market cap
$54.04M
Beta
0.99
P/E (TTM)
-3.4
EPS (TTM)
-$0.32
52W Low $0.70High $1.45

Volume 0.84M

Average 0.29M

RNXT Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

RenovoRx, Inc.NASDAQ: RNXT

Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026

Other income / expenses turns negative

Q1 FY2026 other income / expenses was -$52K, compared with $690K a year earlier. Trailing-twelve-month other income / expenses was $600K. Over 3 fiscal years it compounded at +180.2% a year.

Context

  • Other income / expenses amounted to 119.5% of revenue in FY2025, down 4894.5 pp from a year earlier.
  • Other income / expenses increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly other income / expenses holds near -$52K or moves back toward the trailing-twelve-month quarterly average of $150K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$52K-109.0% QoQ
Last fiscal yearDec 2025
$1.34M-37.8% YoY
LTMMar 2026
$600K-58.5% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-107.5%——
1 year-37.8%——
3-year CAGR+180.2%——
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
1.34M USD
Year-over-year change
-37.8%

Other Income / Expenses vs competitors

How RNXT compares with its peers on the latest reported figures

  • RNXT's LTM Mar 2026 other income / expenses of $600K is the 3rd highest of the 6 companies compared; the peer median is $501.25K.
  • Its year-over-year change of -58.5% is the 5th highest of 6, against a peer median of -49.5%.
  • Other income / expenses amounts to 40.3% of revenue for RNXT, versus a peer median of 114.5%.
RNXT Competitors Peer median
Other Income / Expenses for RNXT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MAIAMAIA Biotechnology, Inc.LTM Mar 2026$1.55M +221.6%+66.4%—
LTRNLantern Pharma Inc.LTM Mar 2026$697.88K -49.5%+70.7%—
RNXTRenovoRx, Inc.LTM Mar 2026$600K -58.5%+180.2%40.3%
ANVSAnnovis Bio, Inc.LTM Mar 2026$501.25K +112.9%+66.3%—
PYPDPolyPid Ltd.LTM Mar 2026-$17.55M -1078.4%——
CELUCelularity Inc.LTM Dec 2025-$30.41M -55.7%—114.5%
Peer median (excluding RNXT) $501.25K-49.5%+66.4%114.5%

Competitors are the stored peer set for RNXT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00043K1.12M
Cost of Revenue0000327K
Gross Profit00043K796K
Gross Margin———100.0%70.9%
Research & Development3.04M4.3M5.67M6.03M6.27M
Selling, General & Admin2.63M5.65M5.73M4.99M7.04M
Operating Expenses5.67M9.95M11.4M11.01M13.31M
Depreciation & Amortization9K6K6K02K
EBITDA(5.48M)(9.83M)(10.12M)(8.81M)(11.17M)
EBITDA Margin———-20497.7%-994.3%
Operating Income(5.67M)(9.95M)(11.4M)(10.97M)(12.51M)
Operating Margin———-25511.6%-1114.0%
Interest Income70K57K0384K427K
Interest Expense904K57K108K00
Other Income / Expenses(653K)61K1.16M2.16M1.34M
Income Before Tax(6.32M)(9.89M)(10.23M)(8.81M)(11.17M)
Pre-Tax Margin———-20497.7%-994.5%
Income Tax Expense00000
Net Income(6.32M)(9.89M)(10.23M)(8.81M)(11.17M)
Net Margin———-20497.7%-994.5%
EPS (Basic)(0.40)(0.54)(0.50)(0.37)(0.32)
EPS (Diluted)(0.40)(0.54)(0.50)(0.37)(0.32)
Weighted Avg Shares17.87M18.1M20.58M23.61M35.33M
Weighted Avg Shares (Diluted)17.87M18.1M20.58M23.61M35.33M

RenovoRx, Inc.

NASDAQ:RNXT

Intrinsic Alpha fair value

Locked

Current Price

$1.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.